These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 20372075)

  • 1. Development of TNFSF as molecular adjuvants for ALVAC HIV-1 vaccines.
    Liu J; Ostrowski M
    Hum Vaccin; 2010 Apr; 6(4):355-9. PubMed ID: 20372075
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The adjuvancy of OX40 ligand (CD252) on an HIV-1 canarypox vaccine.
    Liu J; Ngai N; Stone GW; Yue FY; Ostrowski MA
    Vaccine; 2009 Aug; 27(37):5077-84. PubMed ID: 19573639
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CD40L expressed from the canarypox vector, ALVAC, can boost immunogenicity of HIV-1 canarypox vaccine in mice and enhance the in vitro expansion of viral specific CD8+ T cell memory responses from HIV-1-infected and HIV-1-uninfected individuals.
    Liu J; Yu Q; Stone GW; Yue FY; Ngai N; Jones RB; Kornbluth RS; Ostrowski MA
    Vaccine; 2008 Jul; 26(32):4062-72. PubMed ID: 18562053
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and immunogenicity of a subtype C ALVAC-HIV (vCP2438) vaccine prime plus bivalent subtype C gp120 vaccine boost adjuvanted with MF59 or alum in healthy adults without HIV (HVTN 107): A phase 1/2a randomized trial.
    Moodie Z; Andersen-Nissen E; Grunenberg N; Dintwe OB; Omar FL; Kee JJ; Bekker LG; Laher F; Naicker N; Jani I; Mgodi NM; Hunidzarira P; Sebe M; Miner MD; Polakowski L; Ramirez S; Nebergall M; Takuva S; Sikhosana L; Heptinstall J; Seaton KE; De Rosa S; Diazgranados CA; Koutsoukos M; Van Der Meeren O; Barnett SW; Kanesa-Thasan N; Kublin JG; Tomaras GD; McElrath MJ; Corey L; Mngadi K; Goepfert P;
    PLoS Med; 2024 Mar; 21(3):e1004360. PubMed ID: 38502656
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multimeric soluble CD40 ligand and GITR ligand as adjuvants for human immunodeficiency virus DNA vaccines.
    Stone GW; Barzee S; Snarsky V; Kee K; Spina CA; Yu XF; Kornbluth RS
    J Virol; 2006 Feb; 80(4):1762-72. PubMed ID: 16439533
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of targeted adjuvants for HIV-1 vaccines.
    Liu J; Ostrowski M
    AIDS Res Ther; 2017 Sep; 14(1):43. PubMed ID: 28893282
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Distinct susceptibility of HIV vaccine vector-induced CD4 T cells to HIV infection.
    Auclair S; Liu F; Niu Q; Hou W; Churchyard G; Morgan C; Frahm N; Nitayaphan S; Pitisuthithum P; Rerks-Ngarm S; Kimata JT; Soong L; Franchini G; Robb M; Kim J; Michael N; Hu H
    PLoS Pathog; 2018 Feb; 14(2):e1006888. PubMed ID: 29474461
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhancement of HIV DNA vaccine immunogenicity by the NKT cell ligand, alpha-galactosylceramide.
    Huang Y; Chen A; Li X; Chen Z; Zhang W; Song Y; Gurner D; Gardiner D; Basu S; Ho DD; Tsuji M
    Vaccine; 2008 Mar; 26(15):1807-16. PubMed ID: 18329757
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and Immunogenicity of a Randomized Phase 1 Prime-Boost Trial With ALVAC-HIV (vCP205) and Oligomeric Glycoprotein 160 From HIV-1 Strains MN and LAI-2 Adjuvanted in Alum or Polyphosphazene.
    O'Connell RJ; Excler JL; Polonis VR; Ratto-Kim S; Cox J; Jagodzinski LL; Liu M; Wieczorek L; McNeil JG; El-Habib R; Michael NL; Gilliam BL; Paris R; VanCott TC; Tomaras GD; Birx DL; Robb ML; Kim JH
    J Infect Dis; 2016 Jun; 213(12):1946-54. PubMed ID: 26908741
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HIV gp120 vaccine - VaxGen: AIDSVAX, AIDSVAX B/B, AIDSVAX B/E, HIV gp120 vaccine - Genentech, HIV gp120 vaccine AIDSVAX - VaxGen, HIV vaccine AIDSVAX - VaxGen.
    Adis International Ltd
    Drugs R D; 2003; 4(4):249-53. PubMed ID: 12848591
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune responses to human immunodeficiency virus (HIV) type 1 induced by canarypox expressing HIV-1MN gp120, HIV-1SF2 recombinant gp120, or both vaccines in seronegative adults. NIAID AIDS Vaccine Evaluation Group.
    Clements-Mann ML; Weinhold K; Matthews TJ; Graham BS; Gorse GJ; Keefer MC; McElrath MJ; Hsieh RH; Mestecky J; Zolla-Pazner S; Mascola J; Schwartz D; Siliciano R; Corey L; Wright PF; Belshe R; Dolin R; Jackson S; Xu S; Fast P; Walker MC; Stablein D; Excler JL; Tartaglia J; Paoletti E
    J Infect Dis; 1998 May; 177(5):1230-46. PubMed ID: 9593008
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Head-to-Head Comparison of Poxvirus NYVAC and ALVAC Vectors Expressing Identical HIV-1 Clade C Immunogens in Prime-Boost Combination with Env Protein in Nonhuman Primates.
    García-Arriaza J; Perdiguero B; Heeney J; Seaman M; Montefiori DC; Labranche C; Yates NL; Shen X; Tomaras GD; Ferrari G; Foulds KE; McDermott A; Kao SF; Roederer M; Hawkins N; Self S; Yao J; Farrell P; Phogat S; Tartaglia J; Barnett SW; Burke B; Cristillo A; Weiss D; Lee C; Kibler K; Jacobs B; Asbach B; Wagner R; Ding S; Pantaleo G; Esteban M
    J Virol; 2015 Aug; 89(16):8525-39. PubMed ID: 26041302
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The transcription factor CREB1 is a mechanistic driver of immunogenicity and reduced HIV-1 acquisition following ALVAC vaccination.
    Tomalka JA; Pelletier AN; Fourati S; Latif MB; Sharma A; Furr K; Carlson K; Lifton M; Gonzalez A; Wilkinson P; Franchini G; Parks R; Letvin N; Yates N; Seaton K; Tomaras G; Tartaglia J; Robb ML; Michael NL; Koup R; Haynes B; Santra S; Sekaly RP
    Nat Immunol; 2021 Oct; 22(10):1294-1305. PubMed ID: 34556879
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vaccine Efficacy of ALVAC-HIV and Bivalent Subtype C gp120-MF59 in Adults.
    Gray GE; Bekker LG; Laher F; Malahleha M; Allen M; Moodie Z; Grunenberg N; Huang Y; Grove D; Prigmore B; Kee JJ; Benkeser D; Hural J; Innes C; Lazarus E; Meintjes G; Naicker N; Kalonji D; Nchabeleng M; Sebe M; Singh N; Kotze P; Kassim S; Dubula T; Naicker V; Brumskine W; Ncayiya CN; Ward AM; Garrett N; Kistnasami G; Gaffoor Z; Selepe P; Makhoba PB; Mathebula MP; Mda P; Adonis T; Mapetla KS; Modibedi B; Philip T; Kobane G; Bentley C; Ramirez S; Takuva S; Jones M; Sikhosana M; Atujuna M; Andrasik M; Hejazi NS; Puren A; Wiesner L; Phogat S; Diaz Granados C; Koutsoukos M; Van Der Meeren O; Barnett SW; Kanesa-Thasan N; Kublin JG; McElrath MJ; Gilbert PB; Janes H; Corey L;
    N Engl J Med; 2021 Mar; 384(12):1089-1100. PubMed ID: 33761206
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel prime-boost vaccine strategies against HIV-1.
    Excler JL; Kim JH
    Expert Rev Vaccines; 2019 Aug; 18(8):765-779. PubMed ID: 31271322
    [No Abstract]   [Full Text] [Related]  

  • 16. Natural killer T cell and TLR9 agonists as mucosal adjuvants for sublingual vaccination with clade C HIV-1 envelope protein.
    Singh S; Yang G; Byrareddy SN; Barry MA; Sastry KJ
    Vaccine; 2014 Dec; 32(51):6934-6940. PubMed ID: 25444819
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Induction of human immunodeficiency virus type 1 (HIV-1)-specific cytolytic T lymphocyte responses in seronegative adults by a nonreplicating, host-range-restricted canarypox vector (ALVAC) carrying the HIV-1MN env gene.
    Egan MA; Pavlat WA; Tartaglia J; Paoletti E; Weinhold KJ; Clements ML; Siliciano RF
    J Infect Dis; 1995 Jun; 171(6):1623-7. PubMed ID: 7769304
    [TBL] [Abstract][Full Text] [Related]  

  • 18. DNA vaccine molecular adjuvants SP-D-BAFF and SP-D-APRIL enhance anti-gp120 immune response and increase HIV-1 neutralizing antibody titers.
    Gupta S; Clark ES; Termini JM; Boucher J; Kanagavelu S; LeBranche CC; Abraham S; Montefiori DC; Khan WN; Stone GW
    J Virol; 2015 Apr; 89(8):4158-69. PubMed ID: 25631080
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and immunogenicity of a live recombinant canarypox virus expressing HIV type 1 gp120 MN MN tm/gag/protease LAI (ALVAC-HIV, vCP205) followed by a p24E-V3 MN synthetic peptide (CLTB-36) administered in healthy volunteers at low risk for HIV infection. AGIS Group and L'Agence Nationale de Recherches sur Le Sida.
    Salmon-Céron D; Excler JL; Finkielsztejn L; Autran B; Gluckman JC; Sicard D; Matthews TJ; Meignier B; Valentin C; El Habib R; Blondeau C; Raux M; Moog C; Tartaglia J; Chong P; Klein M; Milcamps B; Heshmati F; Plotkin S
    AIDS Res Hum Retroviruses; 1999 May; 15(7):633-45. PubMed ID: 10331442
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and reactogenicity of canarypox ALVAC-HIV (vCP1521) and HIV-1 gp120 AIDSVAX B/E vaccination in an efficacy trial in Thailand.
    Pitisuttithum P; Rerks-Ngarm S; Bussaratid V; Dhitavat J; Maekanantawat W; Pungpak S; Suntharasamai P; Vanijanonta S; Nitayapan S; Kaewkungwal J; Benenson M; Morgan P; O'Connell RJ; Berenberg J; Gurunathan S; Francis DP; Paris R; Chiu J; Stablein D; Michael NL; Excler JL; Robb ML; Kim JH
    PLoS One; 2011; 6(12):e27837. PubMed ID: 22205930
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.